Activation of Peripheral μ-opioid Receptors by Dermorphin [D-Arg2, Lys4] (1-4) Amide Leads to Modality-preferred Inhibition of Neuropathic Pain.

Author: DongXinzhong, GuanYun, HeShao-Qiu, RajaSrinivasa N, ShechterRonen, ShuBin, TiwariVineeta, TiwariVinod, WangYun, YangFei, ZhangChen, ZhangTong

Paper Details 
Original Abstract of the Article :
BACKGROUND: Opioids have long been regarded as the most effective drugs for the treatment of severe acute and chronic pain. Unfortunately, their therapeutic efficacy and clinical utility have been limited because of central and peripheral side effects. METHODS: To determine the therapeutic value of...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元:
https://pubmed.ncbi.nlm.nih.gov/26756519

データ提供:米国国立医学図書館(NLM)

Dermorphin: A New Oasis in the Desert of Neuropathic Pain

Neuropathic pain, a condition that can make life feel like a scorching desert, is notoriously difficult to treat. This study investigates the potential of dermorphin [D-Arg2, Lys4] (1-4) amide (DALDA), a peripherally acting μ-opioid receptor agonist, as a novel treatment for neuropathic pain. The researchers explored DALDA's effectiveness in rats with spinal nerve ligation-induced neuropathic pain, a model that mimics the burning pain experienced by humans.

A Targeted Approach: A Camel's Perspective

The study revealed that DALDA effectively reduced both heat and mechanical hypersensitivity, but with a stronger effect on heat sensitivity. This targeted approach is like a camel caravan choosing a specific route through a treacherous desert, avoiding dangerous areas while still reaching its destination. The researchers believe that DALDA's effectiveness may be due to its ability to selectively activate μ-opioid receptors in the periphery, minimizing the risk of central side effects.

A Camel's Guide to Pain Management

This study suggests that DALDA may offer a new option for managing neuropathic pain. Its ability to target peripheral μ-opioid receptors while minimizing central side effects could make it a more tolerable and effective treatment. It's important to remember that further research is needed to confirm its efficacy and safety in humans. Like a camel carefully navigating a rocky desert terrain, we need to proceed with caution and explore all potential treatment options before making a final decision.

Dr. Camel's Conclusion

This study offers a glimmer of hope for individuals suffering from neuropathic pain. DALDA's ability to target peripheral μ-opioid receptors and its promising pain-relieving effects suggest its potential as a new treatment option. However, further research is crucial to confirm its effectiveness and safety in humans. In the vast desert of pain management, it's always best to be guided by a knowledgeable camel!

Date :
  1. Date Completed 2016-06-28
  2. Date Revised 2018-11-13
Further Info :

Pubmed ID

26756519

DOI: Digital Object Identifier

NIHMS743808

Related Literature

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.